🇺🇸 Kanglaite in United States

10 US adverse-event reports

Marketing authorisation

FDA

• Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 27 March 2025 – 27 March 2026
• Total reports: 10

Most-reported reactions

1. Acute Coronary Syndrome — 1 report (10%)
2. Death — 1 report (10%)
3. Drug-Induced Liver Injury — 1 report (10%)
4. Dysuria — 1 report (10%)
5. Hepatic Function Abnormal — 1 report (10%)
6. Laryngeal Oedema — 1 report (10%)
7. Liver Function Test Abnormal — 1 report (10%)
8. Myelosuppression — 1 report (10%)
9. Nausea — 1 report (10%)
10. Platelet Count Decreased — 1 report (10%)

Source database →

Frequently asked questions

Is Kanglaite approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Kanglaite in United States?

First Affiliated Hospital of Harbin Medical University is the originator. The local marketing authorisation holder may differ — check the official source linked above.